Cell-based gene therapy offers an alternative strategy for therapeutic angiogenesis for the management of myocardial infarction (MI). However, immune rejection poses a significant obstacle to the implantation of genetically engineered allogeneic or xenogeneic cells. In the present study, an ex vivo gene therapy approach utilizing cell microencapsulation was employed to deliver vascular endothelial growth factor (VEGF) to ischemic myocardium. Chinese hamster ovary (CHO) cells were genetically modified to secrete VEGF and enveloped into semipermeable microcapsules. In vitro assay indicated that the microencapsulated engineered CHO cells could secrete VEGF as high as 3852 pg ml À1 per 48 h at day 8 after encapsulation. Then the microencapsulated CHO cells were implanted into the injured myocardium in a rat MI model, while engineered CHO cells, blank microcapsules and serum-free culture media were implanted as controls. The humoral immunity to xenogeneic CHO cells were evaluated and we found that the titer of anti-CHO antibodies was significantly lower in the microencapsulated CHO transplantation group than the group receiving unencapsulated CHO cells at two weeks after implantation. However, 1 week later, there was almost no difference between these groups. Histology and western blotting confirmed that the microencapsulated CHO cells maintained their original structure and VEGF secretion three weeks after implantation. The capillary density in the treatment region was also significantly higher in the microencapsulated CHO cell group than control groups, which was consistent with gross heart functional improvement. These data suggest that microencapsulated xenogeneic cell-based gene therapy might be a novel approach for therapeutic angiogenesis in ischemic heart disease.
Introduction
Myocardial infarction (MI) is one of the leading causes of morbidity and mortality all over the world. Coronary artery bypass grafting and percutaneous coronary interventions have been the standard treatments for MI. However, approximately 10% of patients are not ideal candidates for standard revascularization treatments due to diffuse coronary disease and large area of infarcted myocardium. A growing body of evidence has indicated that supplementation of angiogenic factors can stimulate new blood vessel growth and restore perfusion in damaged or ischemic myocardium. 1 Thus, by introducing angiogenic factors into the infarcted myocardium, therapeutic angiogenesis might offer a new supplementary strategy, especially for patients who are not suitable for conventional revascularization treatment. 2 Various growth factors have been tested in pre-clinical studies with promising angiogenic ability, including vascular endothelial growth factor (VEGF) family, fibroblast growth factor family and hypoxia-inducible factor. In general, these angiogenic factors were delivered in the form of recombinant proteins or by gene transfer using viral or non-viral vectors. Although the biological effects of these angiogenic factors are well understood, these therapies are not yet to prove clearly efficacious in clinical trials. [3] [4] [5] Since cell transplantation can deliver the cells into the defective area, the combination of gene transfer and cell transplantation strategies emerged as a promising approach for MI. 6, 7 Until now, various autologous cell types, including bone marrow-derived stromal cells and skeletal musclederived myoblasts, have been utilized in cell-based gene therapy for MI. In clinical settings, autologous cells are isolated from patients and often require in vitro expansion prior to transplantation. However, during emergencies, it is impractical to carry out this time-consuming cell manipulation. Furthermore, sometimes adequate numbers of autologous cells may not be achieved due to various reasons including the impairment of cell proliferation with aging. 8 Therefore, an allogeneic or xenogeneic 'cell bank' should be established as a 'universal' cell source to fulfill the requirements of clinical communities. However, immune rejection poses a significant obstacle to the transplantation of xenogeneic cells. To overcome this problem, here we introduce the microencapsulation technique to shelter the implanted xenogeneic cells from the recipient's immune system without altering transgene expression. Microcapsules have a semipermeable membrane, which allows the free exchange of oxygen, nutrients and small secretory proteins but excludes the passage of immunocytes, antibodies and complement factors. 9 Many previous studies have suggested that microencapsulation of xenogeneic cells is adequate but not enough for the complete avoidance of the host immune response. [10] [11] [12] [13] Although there are still some technical and biological limitations that should be overcome before it can be translated into clinical use, the microencapsulation technique has been extensively investigated in many fields of xenogeneic cell and tissue transplantation and is a promising immunoisolation approach.
We enveloped xenogeneic Chinese hamster ovary (CHO) cells engineered to express VEGF into microcapsules and delivered into the infarcted myocardium. In this study, we wanted to assess: (1) microencapsulated cell survival after implantation into the continuously beating heart; (2) whether microencapsulation technology protects xenogeneic cells from immune rejection and (3) whether microencapsulated genetically-modified cells could augment angiogenesis and improve heart function.
Results
Transfection and in vitro expression of VEGF by microencapsulated engineered CHO cells A mammalian expression plasmid pcDNA3-VEGFhemagglutinin (HA) was constructed and stably transfected into CHO cells. The CHO cells were sensitive for plasmid transfection, and the efficiency of liposome transfection was more than 70%. The positive transfectants were collected and expanded in selective media. After encapsulation, the CHO cells gradually multiplied and occupied the most space in the microcapsule about 1 week later. As the cell number increased, VEGF was increasingly secreted into the supernatant of the culture medium ( Figure 1 ). The VEGF concentration was elevated to 3852 pg ml À1 per 48 h at day 8 and then maintained at this level for at least four weeks. We thus chose this time point to implant the microcapsules into rat MI models.
Transplantation of microencapsulated engineered CHO cells improved damaged heart function
Myocardial infarction was induced in Sprague-Dawley rats by ligation of the left anterior artery. After three weeks, surviving rats were randomized into four groups: MC-CHO group, CHO group, MC group and control group, (n ¼ 12 per group), which were treated with microencapsulated engineered CHO cells, engineered CHO cells, blank microcapsules and culture medium without serum, respectively. The fractional shortening (FS), end-systolic dimension (ESD) and end-diastolic dimension (EDD) of the left ventricle (LV) were measured by echocardiography on the day before transplantation (three weeks after MI), as well as two and three weeks after transplantation. In general, the FS and diameters of LV gradually deteriorated after MI. There was no significant difference in any of the measured parameters among the four groups prior to transplantation (P40.05). However, two to three weeks after transplantation, the decline of FS and LV enlargement in the MC-CHO group were significantly lower than in the other three groups (Po0.05) (Figure 2 ).
Microencapsulated engineered CHO cells secrete VEGF in vivo
To distinguish transgenic VEGF expressed by the implanted engineered CHO cells from its endogenous counterpart, a HA epitope tag was added at the C terminus of VEGF when we constructed the plasmid vector pcDNA3-VEGF-HA. To detect the VEGF-HA fusion protein expressed in situ, a western blotting was performed using anti-HA antibody. We found that HA was much higher in the treatment tissue from the MC-CHO group than from the other groups ( Figure 3 ). This result was consistent with the positive anti-HA immunohistochemical staining observed in the treatment tissue where we injected the microencapsulated cells.
Humoral immunity to CHO cells indicated by antibody titer
To evaluate humoral immunity against the implanted xenogeneic CHO cells, the titers of recipient serum antibody against CHO cells were assayed by enzymelinked immunoadsorbent assay (ELISA) at two and three weeks after transplantation (Figure 4 ). At two weeks after transplantation, the antibody titer in the MC-CHO group was significantly lower than in the CHO group (0.6170.075 vs 1.23670.077, Po0.001) although it was still higher than in the MC and control groups, which did not receive any cells. Interestingly, the antibody titer in the MC-CHO group dramatically increased in the following week and almost reached the level of the CHO group (1.15670.065 vs 1.30470.096, P ¼ 0.024). No such increase was observed in the other groups. These results suggested that microcapsules can partially suppress or delay the humoral immune reaction to enveloped xenogeneic cells, but this protective effect is dramatically decreased during three weeks after transplantation.
Histological examination
The ligation of proximal left coronary artery led to transmural infarction in the anterior walls of all examined rats, and fibrous scar tissue developed in the infarcted area. In hematoxylin-eosin stained slides from rats killed at two weeks after transplantation (Figure 5b ), microcapsules containing engineered CHO cells retained their original round or oval structure. Few inflammatory and fibrotic cells were scattered in the surrounding myocardium. One week later (Figure 5c ), more polymorphocytes and lymphocytes accumulated around and infiltrated the microcapsules, indicating a considerable inflammatory response. Two to three weeks after transplantation, many new small vessels were found in regions injected with microencapsulated engineered CHO cells, especially directly around the microcapsules.
To evaluate the viability and transgenic VEGF expression of microencapsulated CHO cells, immunohistochemical Microencapsulated cell-based gene therapy for MI H Zhang et al Figure 4 Anti-Chinese hamster ovary (CHO) cell antibody titers in serum of recipient rats at two and three weeks after transplantation. All sera were diluted with 1:64 before enzyme-linked immunoadsorbent assay detection. The implanted CHO cells had provoked remarkable humoral immune reaction 2 weeks after transplantation. However, the titers were significantly lower in the MC-CHO group than in the CHO group at week 2 (a), but this difference almost vanished at week 3 (b). Microencapsulated cell-based gene therapy for MI H Zhang et al staining was done using anti-HA antibody. In spite of local inflammatory response, HA-positive CHO cells were identified abundantly in the microcapsule ( Figure  5d ). In contrast, there were no surviving CHO cells found in the treatment region in the group receiving naked CHO cells.
Capillary-density analysis
To further evaluate the therapeutic angiogenic effect of microencapsulated engineered cells, the density of small blood vessels was calculated in the treatment area with von Willebrand factor immunohistochemical staining. ; Po0.05, respectively) ( Figure 6 ).
Discussion
Therapeutic angiogenesis by introducing angiogenic factors into the infarcted myocardium has great potential in the treatment of MI, especially for patients not suitable for conventional therapy. Many pre-clinical studies have indicated that VEGF is one of the most powerful modulators of vascular biology, while several completed randomized controlled VEGF clinical trials have not yet provided convincing evidence of its therapeutic efficacy. 14 The most likely explanation for this discrepancy is that the growth factor concentration in target tissues had not reached sufficient levels and/or had not persisted long enough for triggering relevant vascular growth. Besides relatively low efficiency, biosafety is another concern for conventional gene transfer vectors. 15 Therefore, cell-based gene therapy has been developed as a promising new approach for the transfer of therapeutic agents. 6, 7 However, when allogeneic or xenogeneic cells were selected for this purpose, immune rejection is a crucial barrier for cell survival and proliferation. To our knowledge, this is the first study to introduce the microencapsulation technique into the field of cell-based gene therapy for MI. In the present study, VEGFtransfected CHO cells were microencapsulated and then implanted into infarcted myocardium. The major findings in this study are the following: (1) alginate-poly-L-lysine-alginate (APA) microcapsule used in our study can survive in the beating heart; (2) the microcapsule can suppress or delay the immune response to the implanted xenogeneic graft for at least for three weeks; and (3) VEGF secreted by locally implanted microencapsulated engineered CHO cells can augment angiogenesis and improve global heart function.
Microencapsulation was first introduced into the cell or tissue transplantation field by Lim and Sun in 1980. 16 Theoretically, the microcapsule supplies a safe refuge for the implanted xenogeneic cells to escape from recognition and attack by the recipient's immune system. Significant progress has been made toward the successful transplantation of microencapsulated cells in experimental animal models and pilot clinical trials, as discussed in some excellent reviews. 17, 18 However, in most previous studies, the sites for microcapsule transplantation were hollow cavities such as the peritoneal and subarachnoid cavity. To our knowledge, microencapsulated cells have not been implanted into the damaged myocardium. Compared with the peritoneal cavity, even after MI, the heart would provide relatively higher oxygen and nutrient concentration for the microcapsule. 19 However, the continuous mechanical pumping of the heart may have a profound influence on the fate of implanted microcapsules. In this study, the majority of implanted APA microcapsules retained their structure after transplantation for three weeks. This suggests that the APA microcapsules we used are able to tolerate the mechanical squeezing force and high pressure in myocardial tissue.
Although we found that the immunogenicity of xenogeneic CHO cells was remarkably reduced after microencapsulation, the humoral and cellular immune response still occurred after implantation, in association with increased non-specific inflammation (Figures 4 and  5 ). These observations were consistent with other studies for implantation in peritoneal cavities. 20 Three weeks after transplantation, we found that inflammatory cells accumulated around the implanted microcapsules, and the inflammatory and fibrotic reaction consequently affected the efficiency of material exchange between the microencapsulated cells and the surrounding environments. Two factors may account for the inflammatory and fibrotic response: (1) the biocompatibility of ). The number of capillaries increased significantly after three weeks in treatment of myocardium from the MC-CHO group, as compared with the other three groups (e).
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H Zhang et al chemical compounds of the microcapsule itself and (2) the immunoisolation efficiency of microcapsules. First, in the blank microcapsule transplantation group, fibrosis also occurred around the microcapsule, though it was much less severe than in the microencapsulated CHO group. This indicated that the chemical components of the microcapsule itself could provoke an inflammatory response in myocardium. Secondly, the anti-CHO cells antibody titers were also gradually elevated at three weeks in the MC-CHO group, and almost reached the same levels as the CHO group (Figure 4) , which indicated that the recipient had recognized and attacked the microencapsulated CHO cells. The possible rupture of microcapsule (although histological examination did not yield any evidence of this) or leakage of small soluble antigens from CHO cells could expose the enveloped CHO cells to the host's immune system. 20 This result supports the hypothesis that a semipermeable membrane can delay but not completely prevent host immune rejection of xenogeneic grafts.
The in vivo study showed that microencapsulated VEGF-cDNA-transfected CHO cells could augment angiogenesis in ischemic myocardium and improve heart function. We detected the in situ VEGF expression and secretion in the treatment area by western blot and immunohistological assay (Figures 3 and 5 ). These results excluded the possible interference from endogenous VEGF by using an additional epitope tag on the transgenic VEGF. Microencapsulated engineered CHO cells significantly increased the density of newborn capillary in treatment regions when compared with direct transplantation of engineered CHO cells or blank controls. Under the protection of microcapsules, implanted xenogeneic CHO cells could survive and maintain transgene expression for at least three weeks in this study. However, because of immune rejection, engineered CHO cell transplantation without the protection of microcapsules did not improve the angiogenesis in the damaged myocardium. Our results were similar to reports of syngeneic VEGF transgene-modified myoblasts and heart cells implanted into injured myocardium. In Yau's 21 study, the VEGF transgene expression from the transplanted syngeneic cells lasted approximately four weeks. It has been reported that persistent or uncontrolled VEGF expression might result in excessive angiogenesis or angioma formation. 22 Therefore, temporally limited VEGF expression may provide greater safety while still achieving the desired angiogenic effects. However, further investigation should be done to clarify the appropriate level and duration of VEGF transgene expression, as well as the lifetime of microencapsulated xenogeneic grafts in myocardium.
The first limitation of microencapsulated genemodified cell therapy is that microcapsules cannot be removed from the heart after the implantation into the myocardium. Theoretically, microcapsules would dissolve slowly and the enclosed xenogeneic cells would eventually be digested by the host macrophages. However, further study is needed to evaluate the biosafety and long-term influence of the chemical compounds of the microcapsule on the myocardium. 23, 24 Secondary, if allogeneic or xenogeneic stem cells were selected for microencapsulation, the semipermeable membrane would isolate the implanted stem cells from host cardiac tissue. Therefore, microencapsulated stem cells would be unable to interact with the cardiac micro-environment, which may prevent differentiation into cardiomyocytes and regeneration of the host myocardium. However, it has been generally accepted that angiogenic factors may be a crucial contributor to the therapeutic effects of stem cell therapy. 25 Hence we believe that the supplementation of growth factors from implanted xenogeneic cells can foster the formation of arterial collaterals, improve myocardial perfusion and thus also promote the regeneration of damaged myocardium.
The present study is only the first step to introduce the technique of microencapsulation into the field of cardiac therapeutic angiogenesis, and more studies are needed to select more biocompatible membrane material, optimize the encapsulation technology and establish a more suitable permeability cutoff value for the purpose of better immune protection for grafted xenogeneic cells. Furthermore, although integrity and overall stability of microcapsules were confirmed by direct implantation into myocardium, in vitro swelling and/or mechanical assays are needed to further characterize microcapsules.
In conclusion, the present study showed for the first time that transplantation of microencapsulated engineered xenogeneic CHO cells could augment angiogenesis and improve heart function in post-infarction myocardium. The cell microencapsulation technique might become a novel approach for xenogeneic cellbased gene therapy and therapeutic angiogenesis for the treatment of ischemic heart diseases.
Materials and methods

Construction of plasmid pcDNA3-VEGF-HA
To construct VEGF expression vector, the rat VEGF cDNA (GenBank no. NM_031836) was cloned from the left ventricular myocardium of a healthy SpragueDawley rat. To distinguish the exogenous transgene VEGF from its endogenous counterpart in the following study, we added an HA tag sequence at the tail of VEGF cDNA. Due to its small size, the HA segment is unlikely to affect the biochemical properties of VEGF-HA fusion protein. 26 The primers used in PCR for amplification of rat VEGF cDNA (645 bp) were:
Forward: 5 0 -GGTACCATGAACTTTCTGCTCTCTTGGG Reverse: 5 0 -GAATTCTTAAGCGTAATCCGGAACATC GTATGGGTACCGCCTTGGCTTGTCACATCTGC. (The sequence expressed in bold italics with underline encodes the HA tag.)
The PCR product was cloned into the multiple cloning region between KpnI and EcoRI restriction sites of pcDNA3 mammalian expression vector (Invitrogen, Carlsbad, CA, USA), harboring a cytomegalovirus promoter and a gene for neomycin resistance. The recombinant plasmid was confirmed by restriction-pattern identification and DNA-sequencing analyses (AuGCT biotechnology, Beijing, China).
Cell culture and stable transfection
Chinese hamster ovary cells (Cell Bank of Chinese Academy of Medical Sciences, Peking Union Medical College, China) were maintained in Dulbecco's modified Eagle's medium (Invitrogen Corporation) plus 10% fetal bovine serum (Gibco BRL, Carlsbad, CA, USA) at 37 1C and 5% CO 2 . When the cells were 80-90% confluent, the Microencapsulated cell-based gene therapy for MI H Zhang et al plasmid pcDAN3-VEGF-HA was transfected into CHO cells using Lipofectamine 2000 kit (Invitrogen). Stable transfectants were selected by 0.8 mg ml À1 G418 (SigmaAldrich, St Louis, MO, USA) and expanded.
Cell microencapsulation
Alginate-poly-L-lysine-alginate microcapsules containing engineered CHO cells were constructed as described previously with some modification. 27, 28 Briefly, exponentially growing engineered CHO cells were harvested and resuspended in a 1.5% (w v
À1
) filter-sterilized sodium alginate solution (Sigma-Aldrich) in the density of 2 Â 10 6 cells ml
. Then the cell suspension was extruded through a 0.4-mm needle into a 100 mM CaCl 2 solution using an electrostatic droplet generator (4000 V) to form calcium alginate gel beads. The needle tip was 2 cm high above the CaCl 2 solution, and flow-rate of the extruding cell suspension was set as 10 ml h
. After being gelled for 20 min, the microbeads were incubated with 0.05% (w v
) poly-L-lysine (MW 20 700; Sigma-Aldrich) to form alginate-poly-L-lysine membrane around the surface. Then, 0.15% alginate solution was added to counteract excess charges on the membranes for 5 min. At last, the membrane-enclosed gel beads were further suspended in 55 mM sodium citrate to liquify the alginate gel core. Blank microcapsules were prepared by substituting the cell suspension with 1.5% sodium alginate solution. The resulting APA microcapsules were 200-250 mm in diameter. The microcapsules containing engineered CHO cells were cultured in the same way as the original CHO cells in selective media.
In vitro VEGF expression
Morphological investigation of microcapsules was carried out by phase-contrast light microscopy to survey the viability and reproduction of the enveloped cells. The culture media for microencapsulated engineered CHO cells were refreshed every 2 days. To confirm the secreting efficiency of VEGF-HA, the supernatant of discharged culture medium was collected and analyzed for VEGF using an ELISA Kit (R&D Systems, Minneapolis, MN, USA). All procedures were preformed according to the manufacturer's instruction.
Experimental model
Myocardial infarction was induced in eight-week-old male Sprague-Dawley rats (280-300 g) as described previously. 29, 30 All animal experimental procedures were approved by the Ethics Committee for Animal Study in Fuwai Hospital and conformed to the guidelines in the 'Regulation to the Care and Use of Experimental Animal (1996) of the Beijing Council on Animal Care'. Briefly, the animals were oral-tracheal intubated with an 18-gauge intravenous catheter, and ventilated at a rate of 65 cycles/min with a tidal volume of 2.5 ml under room air supplemented with oxygen (0.2 L/min) and 1.0-2.0% isoflurane (Abbott Laboratories, Abbott Park, IL, USA) using a Harvard ventilator (model 683, Harvard Apparatus, USA). After the chest was cleaned and shaved, through a left lateral thoracotomy, the proximal left coronary artery was circumferentially ligated with a 6-0 prolene suture (Johnson & Johnson, Somerville, NJ, USA). After myocardial ischemia was confirmed by regional myocardial color changing, the incision was closed in layers with 3-0 silk running sutures. Three weeks after infarction, the surviving rats with left ventricular FS at the range of 25-30% were randomized into four groups: microencapsulated engineered CHO group (MC-CHO), engineered CHO group (CHO), blank microcapsule group(MC) and serum-free media injection control group(control), (n ¼ 12, respectively). Then the chest was reopened by sternotomy. The microcapsules or cells were then transplanted by intramyocardial injection at five sites in and around the infarcted region with a 29-gauge insulin syringe (BD, Franklin Lakes, NJ, USA). Immunosuppressant was not administered after transplantation.
Transthoracic echocardiography assessment
Immediately before and three weeks after transplantation, LV dimension and function were assessed by twodimensional echocardiography on isoflurane-anesthetized animals. Transthoracic echocardiography was performed using a 12.5 mHz linear-array probe especially designed for cardiac ultrasonic studies in rat models, with an HP sonos 7500 Imaging System. LV EDD and ESD were measured from the short-axis view of the LV at the papillary muscle level. FS, as a sensitive marker of systolic function, was calculated as FS (%) ¼ ((EDDÀESD)/EDD) Â 100. All measurements were performed three times in a blinded fashion.
Western blotting
Western blotting was performed to identify the in situ expression of VEGF-HA fusion protein. Tissues were obtained from the treated area of the LV wall in four rats from the MC-CHO group and one rat from the other three groups. These samples were homogenized on ice in a homogenization buffer (1 mmol l À1 Tris Á Cl, pH7.6, 1 mmol l À1 phenylmethane-sulfonylfluoride, 1 mmol l À1 ethylenediaminetetraacetic acid, 2 mg ml À1 aprotinin). Tissue lysates were subjected to sodium dodecylsulfatepolyacrylamide gel electrophoresis, followed by standard western blotting procedures. The HA tag of the fusion protein VEGF-HA was detected with anti-HA monoclonal antibody (Cell Signaling, Danvers, MA, USA), using b-actin as internal standard. Horseradish peroxidase-linked secondary antibodies (Zhongshan Golden Bridge, Beijing, China) were used and proteins were visualized by enhanced chemiluminescence. The bands were then exposed to radiography film, followed with density quantitation by TotalLab image analysis software.
Evaluation of humoral immune reaction after transplantation
Two weeks after transplantation and upon sacrifice of recipient rats 1 week later, about 0.3 ml blood was obtained from the tail vein of the rats, allowed to clot and centrifuged for 10 min at 4 1C. All the obtained serum was stored at À80 1C before simultaneous analysis of the anti-CHO cell antibody using a cell-based ELISA. 20, 31 Briefly, engineered CHO cells (the same cell lines prepared for microencapsulation and transplantation) were cultured on flat-bottomed 96-well plates and grown to confluence. After removing culture media, the wells were rinsed once with 200 ml per well of phosphatebuffered saline (PBS) and fixed at room temperature with 1% glutaraldehyde in PBS for 1 h. Then the cells were rinsed twice with PBS and blocked overnight at room temperature with 5% skim milk powder in PBS. The cells were again rinsed twice and incubated in triplicate with serial dilutions of serum (50 ml, 1:32-1:1024 in 0.05% Tween 20 in PBS) for 1 h at 37 1C. The cells were rinsed four times and incubated with horseradish peroxidaseconjugated anti-rat immunoglobulin (Zhongshan Golden Bridge) for 1 h at room temperature. After rinsing with PBS four times, a 3,3 0 , 5,5 0 tetramethylbenzidine substrate reagent set (Zhongshan Golden Bridge) was added and incubated for 30 min at room temperature. H 2 SO 4 (50 ml, 1 M) was added to stop the reaction. The plates were read at 450 nm, subtracting the 620 nm wavelength and the absorbance in 1:64 dilution was reported.
Histology examination
The hearts were harvested and fixed in 10% formalin, embedded in paraffin and sectioned. Tissue sections were routinely immunohistochemically stained and with hematoxylin-eosin as described elsewhere. 29 A rabbit polyclonal antibody against HA tag (Cell Signaling) was used to detect the VEGF-HA fusion protein expressed by the implanted microencapsulated engineered CHO cells (HA tag was used to distinguish the exogenous transgene VEGF from the endogenous VEGF expressed by the recipient). Sections were also immunostained with an antibody against von Willebrand factor. The capillary density was determined as the average number of von Willebrand factor-positive small vessels with a diameter less than 100 mm in a field of high magnification ( Â 40, 0.13 mm 2 ). Five fields were randomly selected in each specimen and the capillary density was expressed as their average.
Statistical analysis
All data are expressed as mean7s.d., and SPSS 13.0 for windows (SPSS, Chicago, IL, USA) was used for the statistical analysis. Comparisons of continuous variables among the four groups were performed by a one-way analysis of variance. A value of Po0.05 was considered significant.
